Related Experiment Video
Updated: Jun 17, 2026

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
Published on: January 28, 2019
Vaccine Take of RV3-BB Rotavirus Vaccine Observed in Indonesian Infants Regardless of HBGA Status
Celeste M Donato1,2,3, Amanda Handley1,4, Sean G Byars5
1Enteric Diseases Group, Murdoch Children's Research Institute.
Insights
Histo-blood group antigen (HBGA) status did not impact the effectiveness of the G3P[6] rotavirus vaccine RV3-BB in Indonesian infants. The vaccine demonstrated high vaccine take rates regardless of an infant's HBGA phenotype.
Area of Science:
- Immunology
- Vaccinology
- Genetics
Background:
- Histo-blood group antigen (HBGA) expression influences rotavirus P genotype binding.
- Understanding HBGA's role is crucial for vaccine efficacy, particularly for rotavirus vaccines.
Purpose of the Study:
- To investigate the association between HBGA status and vaccine take of the G3P[6] rotavirus vaccine RV3-BB.
- To determine if secretor and Lewis phenotypes affect RV3-BB vaccine immunogenicity and viral shedding.
Main Methods:
- DNA analysis of FUT2 and FUT3 genes from infant stool samples to determine HBGA status (secretor and Lewis phenotypes).
- Assessment of vaccine take based on serum immune response (IgA, neutralizing antibodies) and/or stool viral excretion.
- Stratification of participants by HBGA status to analyze vaccine take measures.
Main Results:
- HBGA status (secretor and Lewis phenotypes) was determined for 147 out of 164 infants.
- A high cumulative vaccine take rate of 97.9% was observed across participants.
- No significant association was found between HBGA status (secretor or Lewis phenotype) and overall vaccine take or its individual components.
Conclusions:
- The G3P[6] rotavirus vaccine RV3-BB achieves high vaccine take in Indonesian infants.
- HBGA status does not appear to influence the efficacy of the RV3-BB vaccine in this population.
Background:
Histo-blood group antigen (HBGA) status may affect vaccine efficacy due to rotavirus strains binding to HBGAs in a P genotype-dependent manner. This study aimed to determine if HBGA status affected vaccine take of the G3P[6] neonatal vaccine RV3-BB.
Methods:
DNA was extracted from stool samples collected in a subset (n = 164) of the RV3-BB phase IIb trial in Indonesian infants. FUT2 and FUT3 genes were amplified and sequenced, with any single-nucleotide polymorphisms analyzed to infer Lewis and secretor status. Measures of positive cumulative vaccine take were defined as serum immune response (immunoglobulin A or serum-neutralizing antibody) and/or stool excretion of RV3-BB virus. Participants were stratified by HBGA status and measures of vaccine take.
Results:
In 147 of 164 participants, Lewis and secretor phenotype were determined. Positive vaccine take was recorded for 144 (97.9%) of 147 participants with the combined phenotype determined. Cumulative vaccine take was not significantly associated with secretor status (relative risk, 1.00 [95% CI, .94-1.06]; P = .97) or Lewis phenotype (relative risk, 1.03 [95% CI, .94-1.14]; P = .33), nor was a difference observed when analyzed by each component of vaccine take.
Conclusions:
The RV3-BB vaccine produced positive cumulative vaccine take, irrespective of HBGA status in Indonesian infants.
Related Concept Videos
Vaccinations
Bacterial Gastroenteritis
Poliomyelitis
Respiratory Syncytial Virus Disease

